Table 1. Summary of the antihypertensive actions, pharmacokinetics and side effects of four generations of DHP CCBs.
DHP CCBs | First generation | Second generation | Third generation | Fourth generation |
Antihypertensive actions: | ||||
L-type Ca channel block | +++ | +++ | ++ | ++ |
N-type Ca channel block | − | − | − | + |
Onset | Rapid | Gradual | Slow | Slow |
Strength | Strong | Strong | Strong | Strong |
Duration | Short-acting | Moderate | Long-lasting | Long-lasting |
Renoprotection | − | − | + | ++ |
Vasodilation | +++ | +++ | +++ | +++ |
Sympathoexcitation | +++ | ++ | + | − |
Blood norepinephrine | ↑ | ↑ | − | − |
Tolerated | Badly | Badly | Well | Well |
Pharmacokinetics | ||||
Half-life, h | 2 | 7 | 10–36 | 7.5–10 |
Lipophilic | + | + | ++ | +++ |
Side-effects | ||||
Hypotension | + | + | + | + |
Tachycardia | +++ | ++ | − | |
Headache | +++ | ++ | + | |
Flushing | +++ | ++ | + | + |
Edema | ++ | ++ | + | − |
CCB: calcium channel blocker; DHP: dihydropyridine. +: strong; ++: very strong; +++: strongest.